Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19 patients.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	No Debt
Equity-to-Asset	0.87
Interest Coverage	18364.63
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	21.67	Distress Grey Safe
Beneish M-Score	-3.01	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	12.2
	3-Year EBITDA Growth Rate	14.2
	3-Year EPS without NRI Growth Rate	14
	3-Year FCF Growth Rate	32.7
	3-Year Book Growth Rate	18.3
	Future 3-5Y EPS without NRI Growth Rate	3.3
	Future 3-5Y Total Revenue Growth Rate	4.9

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	0.17
	9-Day RSI	3.62
	14-Day RSI	11.13
	6-1 Month Momentum %	30.03
	12-1 Month Momentum %	50.54

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.53
	Quick Ratio	4.37
	Cash Ratio	3.2
	Days Inventory	299.23
	Days Sales Outstanding	107.84
	Days Payable	125.88

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.66
	Dividend Payout Ratio	0.41
	3-Year Dividend Growth Rate	-7.2
	Forward Dividend Yield %	1.72
	5-Year Yield-on-Cost %	5.53
	Shareholder Yield %	1.57

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	67.67
	Operating Margin %	42.54
	Net Margin %	31.5
	FCF Margin %	31.36
	ROE %	21.05
	ROA %	17.64
	ROIC %	31.38
	ROC (Joel Greenblatt) %	58.91
	ROCE %	28.3
	Years of Profitability over Past 10-Year	10

GF Value Rank

3/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	25.68
	Forward PE Ratio	23.87
	PE Ratio without NRI	25.68
	Shiller PE Ratio	45.04
	Price-to-Owner-Earnings	26.22
	PEG Ratio	0.81
	PS Ratio	8.09
	PB Ratio	5.1
	Price-to-Tangible-Book	5.16
	Price-to-Free-Cash-Flow	25.91
	Price-to-Operating-Cash-Flow	21.88
	EV-to-EBIT	17.15
	EV-to-Forward-EBIT	16.5
	EV-to-EBITDA	17.15
	EV-to-Forward-EBITDA	15.38
	EV-to-Revenue	7.35
	EV-to-Forward-Revenue	7.04
	EV-to-FCF	23.55
	Price-to-Projected-FCF	2.09
	Price-to-DCF (Earnings Based)	0.51
	Price-to-DCF (FCF Based)	0.51
	Price-to-Median-PS-Value	1.41
	Price-to-Peter-Lynch-Fair-Value	1.03
	Price-to-Graham-Number	2.43
	Price-to-Net-Current-Asset-Value	7.85
	Price-to-Net-Cash	16.46
	Earnings Yield (Greenblatt) %	5.83
	FCF Yield %	3.86
	Forward Rate of Return (Yacktman) %	22.48

Financials (Next Earnings Date:2024-07-25)

Annual Quarterly TTM

CHGCF's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:CHGCF

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Chugai Pharmaceutical Co Ltd Executives

Details

GF Value: $26.17

CHGCF

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with CHGCF. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	7,119.434
	EPS (TTM) ($)	1.364
	Beta	0.02
	Volatility %	27.45
	14-Day RSI	11.13
	14-Day ATR ($)	0.238049
	20-Day SMA ($)	34.108
	12-1 Month Momentum %	50.54
	52-Week Range ($)	26 - 43.722
	Shares Outstanding (Mil)	1,645.38

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Chugai Pharmaceutical Co Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Chugai Pharmaceutical Co Ltd Stock Events

Financials Calendars

	Event	Date	Price($)
No Event Data

Chugai Pharmaceutical Co Ltd Frequently Asked Questions

What is Chugai Pharmaceutical Co Ltd(CHGCF)'s stock price today?

The current price of CHGCF is $32.43. The 52 week high of CHGCF is $43.72 and 52 week low is $26.00.

When is next earnings date of Chugai Pharmaceutical Co Ltd(CHGCF)?

The next earnings date of Chugai Pharmaceutical Co Ltd(CHGCF) is 2024-07-25.

Does Chugai Pharmaceutical Co Ltd(CHGCF) pay dividends? If so, how much?

The Dividend Yield % of Chugai Pharmaceutical Co Ltd(CHGCF) is 1.66% (As of Today), Highest Dividend Payout Ratio of Chugai Pharmaceutical Co Ltd(CHGCF) was 0.75. The lowest was 0.31. And the median was 0.43. The Forward Dividend Yield % of Chugai Pharmaceutical Co Ltd(CHGCF) is 1.72%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.